# Efficacy of the BELA weight management programme to prevent increase of weight in schizophrenic patients treated with olanzapin (BELA = movement - nutrition - learning - accepting)

Submission date	Recruitment status	Prospectively registered
18/04/2008	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
30/05/2008	Completed	Results
Last Edited	Condition category	☐ Individual participant data
30/05/2008	Mental and Behavioural Disorders	<ul><li>Record updated in last year</li></ul>

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Joachim Cordes

#### Contact details

Clinic and Polyclinic for Psychiatry and Psychotherapy Rheinische Kliniken Düsseldorf Bergische Landstr. 2 Düsseldorf Germany 40629 +49 211 9223402 joachim.cordes@lvr.de

# Additional identifiers

# Protocol serial number

GM2 2007

# Study information

## Scientific Title

## **Acronym**

**BELA** 

## **Study objectives**

To assess the efficacy of preventative effects of the BELA programme on weight and metabolic parameters in schizophrenic patients treated with olanzapin.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

- 1. Ethics Committee of Medical Faculty of Heinrich-Heine University. Date of approval: 07/02/2008 (ref: MC-LKP-249)
- 2. Federal Institute for Drugs and Medical Devices (BfArM). Date of approval: 06/12/2007 (ref: 4033665)

## Study design

Phase IV, multi-centre, open, two-arm randomised controlled trial.

## Primary study design

Interventional

## Study type(s)

Prevention

## Health condition(s) or problem(s) studied

Schizophrenia

#### **Interventions**

This trial is taking place at four sites (Düsseldorf, Bochum, Krefeld, Dortmund). Participants will be randomly allocated to the two arms in equal numbers:

Intervention group: Standard therapy + BELA weight management programme Control group: Standard therapy only

The psychoeducation programme BELA has been developed at the beginning of 2005 for psychiatric patients. The contents of the psychoeducation are based on the knowledge that better nutrition and regular exercise may stabilise the individual course of disease, the detection of bad habits and the implementation, practice and stabilisation of individual, appropriate habits. As far as methods are concerned, these are simple pedagogic and informational modules (adapted to the type of patients) and which result in experiment-orientated, practical exercises. The BELA concept is geared to small groups (6 - 10 patients) in order to, for example, allow the planning, shopping, cooking of a meal. Over a period of 10 weeks there are group meetings, each 60 minutes, with knowledge transfer of nutrition and exercising.

## Content of patient-education:

- 1. Aim of the course
- 2. Energy and calories
- 3. Types of provisions
- 4. Major nutrients
- 5. Pathology
- 6. Planning the day
- 7. Fats
- 8. Recipes
- 9. Cooking with vegetables, etc. (practical)
- 10. Relevance of exercises

## **Intervention Type**

Drug

#### Phase

Phase IV

## Drug/device/biological/vaccine name(s)

Olanzapin

## Primary outcome(s)

Weight changes in kg, measured at week 1 and week 10.

## Key secondary outcome(s))

- 1. Influence of the intervention on further risk factors, assessed by the following:
- 1.2. Cholesterol at Week 2, 1, 5, 10, 14 and 18
- 1.3. low density lipoprotein (LDL) at Week 2, 1, 5, 10, 14 and 18
- 1.4. Triglyzeride at Week 2, 1, 5, 10, 14 and 18
- 1.5. high density lipoprotein(HDL) at Week 2, 1, 5, 10, 14 and 18
- 1.6. HbA1c at Week 1, 10 and 18
- 1.7. Glucose at Week 2, 1, 5, 10, 14 and 18
- 1.8. Blood-pressure at Week 2, 1, 5, 10, 14 and 18
- 1.9. Abdominal girth at Week 2, 1, 5, 10, 14 and 18
- 1.10. Body mass index (BMI) at Week 2, 1, 5, 10, 14 and 18
- 2. Identification of indicators with regard to weight increase and the response on weight management by acquisition of the following parameters:
- 2.1. Age, sex, initial weight 2 weeks prior to intervention
- 2.2. Psycho-pathological rating-scales:
- a. Positive and Negative Syndrome Scale (PANSS) 2 weeks before intervention and then at weeks 1, 5, 10, 14 and 18
- b. Personal social achievement rating scale (persönliche soziale Leistungskala [PSL]) at weeks 1, 10 and 18
- c. 36-item Short Form health survey (SF-36) at weeks 1, 10 and 18
- d. Body image assessment questionnaire (Fragebogen zur Beurteilung des eigenen Körpers [FBeK]) at weeks 1, 10 and 18
- e. Type D Personality Scale (DS14) 2 weeks prior to intervention
- f. Global Assessment of Functioning (GAF) at weeks 1, 10 and 18
- 2.3. Medical genetics: Polymorphism for weight increase, assessed at week 1
- 2.4. Lipometabolism: Participating hormones and interleukine: leptin, ghrelin, adiponektin, cortisone, retinol binding protein 4 (RBP-4), IL-6, TNF-alpha. These will be assessed at weeks 1,

10 and 18

3. Increase of weight (in kg) of the intervention group in comparison to the control group at the end of the follow-up phase (Week 1 [before the intervention phase] vs Week 18 [after the follow-up phase])

## Completion date

15/11/2010

# **Eligibility**

## Key inclusion criteria

- 1. Both males and females
- 2. Age 18 65 years
- 3. Criteria of the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM IV) for schizophrenia or schizoaffective psychosis
- 4. Written informed consent
- 5. Capability of signing informed consent
- 6. Olanzapin medication

## Participant type(s)

Patient

## Healthy volunteers allowed

No

# Age group

Adult

## Lower age limit

18 years

## Sex

All

## Key exclusion criteria

- 1. Serious somatic diseases
- 2. Changes in weight due to somatic diseases
- 3. Pregnancy or lactation
- 4. Increase of weight of more than 3 kg over the last 3 months before start of treatment with olanzapin
- 5. Co-medication with a weight-reducing potential
- 6. Participation in another interventional trial which could interfere with this trial

### Date of first enrolment

03/04/2008

## Date of final enrolment

15/11/2010

# Locations

## Countries of recruitment

Germany

Study participating centre Clinic and Polyclinic for Psychiatry and Psychotherapy Düsseldorf Germany 40629

# Sponsor information

# Organisation

Heinrich-Heine University (Germany)

## **ROR**

https://ror.org/024z2rq82

# Funder(s)

# Funder type

University/education

## **Funder Name**

Heinrich-Heine University (Germany)

## **Funder Name**

Lilly GmbH (Germany)

## Funder Name

Note: This is an investigator initiated trial.

# **Results and Publications**

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet 11/11/2025 No Yes